Logo

PrognomiQ: Brian Koh, Bruce Wilcox

Dec 01, 2022

PrognomiQ has appointed Brian Koh as chief medical officer, a role in which he will be responsible for developing and executing the multiomics company's clinical development and medical strategy. Koh previously served as head of translational sciences and clinical development at Vividion Therapeutics. Prior to that, he held positions of increasing responsibility at both Gilead Sciences and Kite Pharma. He received his undergraduate training at Harvard, and received an MD, MS, and MPhil from Yale University. He also completed a postdoc in clinical pharmacology at Mayo Clinic-Rochester while holding a triple academic appointment as an instructor in the departments of medicine, oncology, and pharmacology.

PrognomiQ said that it has also promoted Bruce Wilcox, one of the company's founding leaders, to the position of chief technology officer. He was previously VP of proteomics.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.